Therini Bio, Inc.

📍 Sacramento, United States🗓 Founded 2016👥 13 employees💰 Last funded Jan 2026
Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. The Company is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease (AD) and Diabetic Macular Edema (DME), where destructive neuroinflammation plays a central role in the disease process. The foundational science was licensed based on technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD). Therini Bio’s top-tier syndicate of life sciences investors includes the Alzheimer’s Drug Discovery Foundation, SV Health Investors’ Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures.
3
Total investors
0
Early stage
0
Mid stage
3
Late stage
2016
Founded
Investor geography3 countries
United Kingdom
1
Germany
1
Japan
1
Investor activity2022–2026 · investors recorded per year
202212025120261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Therini Bio, Inc.?
Therini Bio, Inc. has 3 investors on record on gritt.io and 3 late-stage investors.
When did Therini Bio, Inc. last raise funding?
The most recent investment in Therini Bio, Inc. recorded on gritt.io was in January 2026.
When was Therini Bio, Inc. founded?
Therini Bio, Inc. was founded in 2016.
What industry is Therini Bio, Inc. in?
Therini Bio, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Therini Bio, Inc. based?
Therini Bio, Inc. is headquartered in Sacramento, United States.